KYMR
KYMR clinical trials: Kymera Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Kymera Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 15
- Trials linked
- 12
- As lead sponsor
- 3
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
KYMR on the catalyst calendar · KYMR registry changes
- Primary completion Aug 22, 2026ActualPhase 1NCT07412288First-in-human Study of Orally Administered KT-579 in Healthy Adult ParticipantsKymera Therapeutics, Inc. · Healthy ParticipantsCompletedKYMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2027Sponsor estimatePhase 1NCT07823205A Study to Evaluate Different Oral Formulations of KT-621Kymera Therapeutics, Inc. · Healthy ParticipantsRecruitingKYMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 2NCT07677059A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma StudyKymera Therapeutics, Inc. · Asthma (Diagnosis)RecruitingKYMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 2NCT07323654A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic AsthmaKymera Therapeutics, Inc. · Eosinophilic AsthmaRecruitingKYMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 2NCT07217015A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic DermatitisKymera Therapeutics, Inc. · Atopic DermatitisActive, not recruitingKYMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 10, 2025ActualPhase 1NCT06945458Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)Kymera Therapeutics, Inc. · Atopic DermatitisCompletedKYMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 23, 2025ActualPhase 1NCT06673667First-in-human Study of Orally Administered KT-621 in Healthy Adult ParticipantsKymera Therapeutics, Inc. · Healthy Participants StudyCompletedKYMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 3, 2025ActualPhase 1NCT05225584Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid TumorsKymera Therapeutics, Inc. · Non Hodgkin Lymphoma (NHL)CompletedKYMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 18, 2024ActualPhase 1NCT05775406Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma...Kymera Therapeutics, Inc. · Myeloid MalignanciesCompletedKYMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 28, 2023ActualPhase 1NCT05233033Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHLKymera Therapeutics, Inc. · Non Hodgkin LymphomaCompletedKYMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 20, 2022ActualPhase 1NCT04772885A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or...Kymera Therapeutics, Inc. · Healthy VolunteerCompletedKYMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 24, 2021ActualNo phase registeredNCT04440410Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic DermatitisKymera Therapeutics, Inc. · Hidradenitis SuppurativaCompletedKYMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 17, 2028Sponsor estimatePhase 1NCT07629336SAR447971 First-in-human StudySanofi · HidradenitisRecruitingSNYLeadKYMRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 23, 2025ActualPhase 2NCT06058156Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic DermatitisSanofi · Atopic DermatitisTerminatedSNYLeadKYMRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 9, 2025ActualPhase 2NCT06028230A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe...Sanofi · Hidradenitis SuppurativaTerminatedSNYLeadKYMRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 15 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner